Xanax Related Published Studies
Well-designed clinical trials related to Xanax (Alprazolam)
Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg. [2007.05]
Current approaches to the pharmacologic treatment of anxiety disorders. [2007]
Different acute tolerance development to EEG, psychomotor performance and subjective assessment effects after two intermittent oral doses of alprazolam in healthy volunteers. [2007]
Attenuation of the hypothalamic-pituitary-adrenal axis responsivity to the Trier Social Stress Test by the benzodiazepine alprazolam. [2006.11]
The benzodiazepine alprazolam dissociates contextual fear from cued fear in humans as assessed by fear-potentiated startle. [2006.10.01]
Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs. [2006.10]
Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers. [2006.09]
A statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolam. [2006.05]
A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. [2005.12]
Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. [2005.11]
A neurophysiological study of the detrimental effects of alprazolam on human action monitoring. [2005.10]
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. [2005.09]
Alprazolam significantly improves the efficacy of granisetron in the prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer. [2005.08]
Effects of dehydroepiandrosterone and alprazolam on hypothalamic-pituitary responses to exercise. [2005.08]
A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolam. [2005.06]
Sertraline and alprazolam in the treatment of panic desorder. [2005.05]
Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. [2005.05]
No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. [2005.04]
A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. [2005.02.01]
Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers. [2005]
In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. [2004.10]
The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans. [2004.10]
Response of the hypothalamic-pituitary-adrenal axis to small dose arginine-vasopressin and daily urinary free cortisol before and after alprazolam pre-treatment differs in obesity. [2004.06]
Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers. [2004.06]
Interdose elevation in plasma cortisol during chronic treatment with alprazolam but not lorazepam in the elderly. [2004.03]
Influence of hydroxypropyl methylcellulose polymer on in vitro and in vivo performance of controlled release tablets containing alprazolam. [2003.11]
Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine. [2003.08]
Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. [2003.05]
Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder. [2003.04]
Anticipatory anxiety in moderately to highly-anxious oral surgery patients as a screening model for anxiolytics: evaluation of alprazolam. [2003.02]
Preoperative alprazolam reduces anxiety in ambulatory surgery patients: a comparison with oral midazolam. [2002.12]
The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. [2002.10]
Effects of alprazolam on driving ability, memory functioning and psychomotor performance: a randomized, placebo-controlled study. [2002.08]
Behavioral, psycho-physiological and salivary cortisol modifications after short-term alprazolam treatment in patients with recent myocardial infarction. [2002.01]
Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: a dose-response study. [2001.10]
Effect of alosetron on the pharmacokinetics of alprazolam. [2001.04]
Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-XR for panic disorder. [2001.04]
Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. [2001.02]
New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide. [2000.10]
Effects of repeated ingestion of grapefruit juice on the single and multiple oral-dose pharmacokinetics and pharmacodynamics of alprazolam. [2000.06]
Increased sensitivity to alprazolam in females with a paternal history of alcoholism. [2000.06]
Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam. [2000.06]
Alprazolam-ritonavir interaction: implications for product labeling. [2000.04]
Dose-response evaluation of the interaction between sertraline and alprazolam in vivo. [2000.04]
Predictors of individual differences in alprazolam self-medication. [1999.11]
The inhibitory effect of alprazolam, a benzodiazepine, overrides the stimulatory effect of metyrapone-induced lack of negative cortisol feedback on corticotroph secretion in humans. [1999.08]
Granisetron plus or minus alprazolam for emesis prevention in chemotherapy of lymphomas: a randomized multicenter trial. Granisetron Trialists Group. [1999.07]
Influence of endogenous progesterone on alprazolam pharmacodynamics. [1999.06]
Food "cravings" and the acute effects of alprazolam on food intake in women with premenstrual dysphoric disorder. [1999.06]
Effects of alprazolam on the acoustic startle response in humans. [1999.04]
Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo. [1999]
Mood and performance changes in women with premenstrual dysphoric disorder: acute effects of alprazolam. [1998.12]
Alprazolam 0.125 mg twice a day improves aspects of psychometric performance in healthy volunteers. [1998.10]
Laboratory validation study of drug evaluation and classification program: alprazolam, d-amphetamine, codeine, and marijuana. [1998.10]
Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. [1998.10]
Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. [1998.09]
Noninvasive indices of autonomic regulation after alprazolam and lorazepam: effects on sympathovagal balance. [1998.08]
Functional magnetic resonance imaging of alprazolam-induced changes in humans with familial alcoholism. [1998.05.20]
Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients. [1998.05]
Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. [1998.05]
Single-dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young subjects. [1998.01]
The acute and chronic performance effects of alprazolam and lorazepam in the elderly: relationship to duration of treatment and self-rated sedation. [1998]
Amnestic and anxiolytic effects of alprazolam in oral surgery patients. [1997.10]
Acute and delayed effects of alprazolam on flight phobics during exposure. [1997.09]
Alprazolam in young and elderly men: sensitivity and tolerance to psychomotor, sedative and memory effects. [1997.06]
Behavioral effects of alprazolam in humans. [1997.02]
A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. [1997]
Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients. [1996.11.01]
Effects of alprazolam and lorazepam on catecholaminergic and cardiovascular activity during supine rest, mental load and orthostatic challenge. [1996.11]
Alprazolam in chronic tension type headache. [1996.09]
Diazepam versus alprazolam for the treatment of panic disorder. [1996.08]
A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. [1996.05]
Effects of alprazolam and bromazepam on visual search and verbal recognition memory in humans: a study with event-related brain potentials. [1996]
Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam. [1995.12.13]
Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. [1995.12]
A comparative study of the psychological effects of DN-2327, a partial benzodiazepine agonist, and alprazolam. [1995.10]
Effects of alprazolam on glucose regulation in diabetes. Results of double-blind, placebo-controlled trial. [1995.08]
A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. [1995.07.05]
Comparison of the spectrum of cognitive effects of alprazolam and adinazolam after single doses in healthy subjects. [1995.07]
Treatment of depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo. [1995.07]
Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. [1995.04]
Alprazolam absorption kinetics affects abuse liability. [1995.03]
Comparison of acute alprazolam (0.25, 0.50 and 1.0 mg) effects versus those of lorazepam 2 mg and placebo on memory in healthy volunteers using laboratory and telephone tests. [1995.03]
Acute effects of the anxiolytics suriclone and alprazolam on cognitive information processing utilizing topographic mapping of event-related brain potentials (P300) in healthy subjects. [1995]
Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. [1994.12]
Comparison of ondansentron (GR 38032F) versus ondansentron plus alprazolam as antiemetic prophylaxis during cisplatin-containing chemotherapy. [1994.12]
Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder. [1994.11]
A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder. [1994.10]
Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study. [1994.09]
Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine. [1994.09]
Alprazolam blockade of CO2-provoked panic in patients with panic disorder. [1994.08]
Double-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome: preliminary findings. [1994.08]
The relationship of alprazolam and clonazepam dose to steady-state concentration in plasma. [1994.08]
Alprazolam attenuates vasopressin-stimulated adrenocorticotropin and cortisol release: evidence for synergy between vasopressin and corticotropin-releasing hormone in humans. [1994.07]
Comparison of the efficacy, safety and withdrawal of alpidem and alprazolam in anxious patients. [1994.07]
Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder. [1994.07]
Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? [1994.06]
Alprazolam and exposure for panic disorder with agoraphobia. Attribution of improvement to medication predicts subsequent relapse. [1994.05]
Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. [1994.04]
The stress-, but not corticotropin-releasing hormone-induced activation of the pituitary-adrenal axis in man is blocked by alprazolam. [1994.04]
Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo. [1994.04]
|
